Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vivalis, a biopharmaceutical company, has achieved milestone in its collaboration with GlaxoSmithKline Biologicals (GSK) to develop new influenza vaccines based on Vivalis' EB66 cell line technology.
Subscribe to our email newsletter
Vivalis said that the milestone recognises the completion of the characterisation program of the EB66 cell line according to the current regulatory requirements.
The worldwide collaboration and license agreement is devoted to developing a new way of producing both seasonal and pandemic human influenza vaccines.
Vivalis claimed that the EB66 stem cell line technology developed by it has the potential to provide control and efficiency as compared with the traditional method which uses embryonic chicken eggs.
Majid Mehtali, CSO and Franck Grimaud, CEO, co- managers of Vivalis, said: “We are very pleased with the quality of our collaboration with GSK Biologicals in the area of cell-based influenza vaccine development and with the continued progress of this project. The achievement of this important milestone is the recognition by our partner of the completion of the work done by both our teams to characterize the EB66 cell line.
“This work did represent a major investment for Vivalis over the last three years and is a significant step for the development of the EB66 cell line technology not only in the Influenza vaccine field but for all applications.”